SAN DIEGO, Jun 29, 2011 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced that the University of Washington (UW) Department of Genome Sciences has joined the Illumina Genome Network (IGN). IGN is a global partnership designed to link researchers seeking large-scale whole human genome sequencing services with leading institutions that provide such services using Illumina's sequencing technology.
Recent advancements in Illumina HiSeq(TM) sequencing system technology have enabled the company to lower the price for the service to $5,000 per genome for projects of 10 samples or more, and $4,000 for projects of 50 samples or more. By offering the speed, accuracy and high-quality data researchers require at price points they can afford, the Illumina Genome Network has raised the bar on whole human genome sequencing services.
"Illumina believes making whole genome sequencing more accessible to researchers worldwide is fundamental to enhancing our understanding of human biology and making breakthrough medical advances," said David Bentley, Vice President and Chief Scientist at Illumina. "We are very pleased that the University of Washington's Genomic Sciences Department, one of the world's leading genomic research facilities, now will make its state-of-the-art capabilities broadly available via the Illumina Genome Network."
Formed in 2001, the UW Department of Genome Sciences has used Illumina systems since 2008; its goal is to apply genetic, genomic and computational approaches to today's leading questions in biology and medicine.
All Illumina Genome Network partners are experienced and well-published using Illumina sequencers, and have completed Illumina's CSPro(R) (Certified Service Provider) certification. Each has 10 or more Illumina sequencing systems (Genome Analyzers and/or HiSeq 2000 systems) in their facility, providing the scalability to handle even the largest sequencing projects and the speed to provide data as quickly as possible. The UW Department of Genome Sciences joins the National Center for Genome Resources, Macrogen/Genomic Medicine Institute, and Illumina's own FastTrack Services as members of the Illumina Genome Network.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Kevin Williams, MD, Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Laura Trotter, Public Relations
858-822-6822
pr@illumina.com
